Publication | Open Access
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
10
Citations
0
References
2019
Year
Interim AnalysisOa13.07 Neoadjuvant AtezolizumabMedicineImmunologyClinical TrialsPathologyImmune Checkpoint InhibitorMulticenter Trial Lcmc3PharmacotherapyCancer TreatmentImmunotherapyOncologyRadiation OncologyHealth Sciences
No additional data available for this publication yet. Check back later!